Rational design of drug delivery systems for potential programmable drug release and improved therapeutic effect

Nanoparticle-based combination therapy has been reported as one important treatment strategy to improve therapeutic efficacy in cancer therapy. However, the traditional co-delivery method often suffers from serious coordination issues that fails to account for the differences in the action sites of each of the drugs, greatly counteracting the synergistic effects of combination agents. Herein, we reported a pH-reduction dual responsive drug delivery system for programmable release of combretastatin A-4 (CA4) and cis-platinum (CDDP). According to their spatial and temporal needs, such nanocarriers could firstly release CA4 in the perivascular sites by responding to acidic microenvironment of tumor, then further diffuse throughout the tumor and release CDDP upon redox when being taken by cancer cells. With the help of such spatiotenporal release property, CA4 and CDDP can target the endothelial cells of tumor vessels and cancer cells in succession, giving rise to temporal and spatial synergisms. On one hand, the first released CA4 provided a complementary effect for improving tumor accumulation of nanocarriers and the delivery effect of CDDP. On the other hand, CA4 and CDDP respectively targeted their action sites, overall maximizing the therapeutic effect. More importantly, such spatiotemporal drug delivery ability is accomplished by the pH-reduction dual responsive design of nanocarriers, thus could also serve as a universal approach for programmable release of other combination agents to improve their synergistic effect in cancer therapy.